Douglas S. Lehrer, MD

Department:
Psychiatry
Title:
Professor, Psychiatry
Address:
Cincinnati VAMC, 3200 Vine St, Cincinnati, OH 45220-2213

Certification

  • American Board of Psychiatry and Neurology: Psychiatry, 1993

Academic Interests

  • Phenomenology, pathophysiology, genetics and neuroimaging of schizophrenia-spectrum disorders
  • Forensic Psychiatry
  • Vitamin D

 

Education History

M.D., University of Cincinnati College of Medicine, 1987

Residency, Psychiatry, University of Cincinnati Hospital, 1987-1991

Mental Health Executive Leadership Program, Weatherhead School of Management, Case Western Reserve University, Cleveland, 1996-97

Teaching

History of Psychiatry, Course founder/director emeritus

Clinical teaching, inpatient psychiatry - Cincinnati VA Medical Center

Research Statement

Current activities:

Genomic Psychiatry Cohort (GPC): Site PI, Wright State University. GPC is a multi-site, NIMH-funded effort to create an historically large, open-access repository of genetic material and clinical characterization for people with schizophrenia-bipolar spectrum disorders as well as controls. There are presently over 35,000 subjects within the cohort and we are actively enrolling new participants with emphasis on those with African ancestry. New enrollments will conclude in mid-2020.

Multimodal imaging in schizophrenia: I continue work with my colleagues, Drs. Monte Buchsbaum (U.California, San Diego), Serge Mitelman (Mt. Sinai University) and others, to analyse and interpret a remarkable, locally-acquired dataset of 18-F fallypride PET, FDG PET, MRI (structural, functional, diffusion tensor), and clinical and neuropsychological measures from a cohort of over 30 people with medication-naive schizophrenia, plus matched controls.

Service

Inpatient attending & ketamine psychiatrist, Cincinnati VA Medical Center

Publications

Peer-Reviewed Articles (selected)

Lehrer DS, Christian BT, Mantil J, Murray AC, Buchsbaum BR, Oakes T, Byne W, Kemether EM, Buchsbaum MS.  Thalamic and prefrontal FDG uptake in never-medicated patients with schizophrenia. Am J Psychiatry 2005;162:931–8.

Christian BT, Lehrer DS, Shi B, Narayanan TK, Strohmeyer P, Buchsbaum MS, Mantil J.  Measuring dopamine neuromodulation in the thalamus: Using [F-18]fallypride PET to study dopamine release during a spatial attention task. NeuroImage 2006;31(1):139-52

Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, Shi B, Mantil J, Kemether E, Oakes T, Mukherjee J.  D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res 2006;85(1-3):232-244

Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric Comorbidities and Schizophrenia. Schizophr Bull 2009;35(2):383-402

Mossman D, Bowen MD, Vanness DJ, Bienenfeld D, Correll T, Kay J, Klykylo WM, Lehrer DS. Quantifying the Accuracy of Forensic Examiners in the Absence of a “Gold Standard.” Law & Human Behavior 2010 Oct;34(5):402-17.

Lehrer DS, Christian BT, Kirbas C, Chiang M, Sidhu S, Short H, Wang B, Shi B, Chu K-W, Merrill B, Buchsbaum MS. 18F-Fallypride binding potential in patients with schizophrenia compared to healthy controls. Schizophrenia Research 2010;122(1-3):43-52

Pato MT, Sobell J, Medeiros H, Abbott C, Sklar B, Genomic Psychiatry Consortium, Buckley P, Bromet E, Escamilla M, Fanous A, Lehrer D, Macciardi F, Malaspina D, McCarroll S, Marder S, Morley C, Nicollini H, Perkins D, Purcell S, Rapaport M, Sklar P, Smoller J, Knowles JA, Pato CN. The Genomic Psychiatry Cohort: Partners in Discovery. Am J Med Genet Part B 2013;9999:1–7.

Hartz SM, Pato CN, Medeiros H, Cavazos-Rehg P, Sobell J, Knowles JA, Bierut LJ, Pato MT, Genomic Psychiatry Cohort Consortium (GPCC)*. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry 2014;71(3):248-254

Lehrer DS, Lorenz J. Anosognosia in Schizophrenia: Hidden in Plain Sight. Innovations in Clinical Neuroscience. 2014;11(5-6):10-17.

Lehrer DS, Pato MT, Nahhas RW, Miller BJ, Malaspina D, Buckley PF, Sobell JL, Walsh-Messinger J, Genomic Psychiatry Cohort Consortium, Pato CN. Paternal age effect: Replication in schizophrenia with intriguing dissociation between bipolar with and without psychosis. Am J Med Genet B Neuropsychiatr Genet. 2016 Jun;171(4):495-505.

Malaspina D, Walsh-Messinger J, Antonius D, Dracxler R, Rothman K, Puthota J, Gilman C, Feuerstein JL, Keefe D, Goetz D, Goetz RR, Buckley P, Lehrer DS, Pato M, Pato C, Genomic Psychiatry Cohort Consortium. Parental age effects on odor sensitivity in healthy subjects and schizophrenia patients. Am J Med Genet B Neuropsychiatr Genet. 2016 Jun;171(4):513-520.

Fontanella CA, Campo JV, Phillips GS, Hiance-Steelesmith DL, Sweeney HA, Tam K, Lehrer D, Hurst MA. Benzodiazepine use and risk of mortality among schizophrenia patients: A retrospective longitudinal study. Journal of Clinical Psychiatry. 2016 May;77(5):661-7

Charney AW, et al. Evidence for genetic heterogeneity between clinical subtypes of bipolar disorder. Translational Psychiatry. 2017 Jan 10;7(1):e993.

Mitelman SA, Buchsbaum MS, Christian BT, Merrill BM, Buchsbaum BR, Mukherjee J, Lehrer DS. Dopamine receptor density and white mater integrity: 18F-fallypride positron emission tomography and diffusion tensor imaging study in healthy and schizophrenia subjects. Brain Imaging Behav. 2018 Dec 6. doi: 10.1007/s11682-018-0012-0. [Epub ahead of print]

Charney AW et al. Contribution of rare copy number variants to bipolar disorder risk is limited to schizoaffective cases. Biological Psychiatry. 2019 Jul 15;86(2):110-119. PMID 30686506

McCullough PJ, Lehrer DS, Amend J. Daily oral dosing of vitamin D3 using 5000 TO 50,000 international units a day in long-term hospitalized patients: Insights from a seven year experience. J Steroid Biochem Mol Biol. 2019 May;189:228-239. PMID 30611908

Epi25 Collaborative (241 collaborators). Ultra-rare genetic variation in the epilepsies: A whole-exome sequencing study of 17,606 individuals. Am J Hum Genet. 2019 Aug 1;105(2):267-282. PMID 31327507

Bigdeli TB et al (58 authors). Contributions of common genetic variants to risk of schizophrenia among individuals of African and Latino ancestry. Molecular Psychiatry. 2019 Oct 7. doi: 10.1038/s41380-019-0517-y. [Epub ahead of print]

Mitelman SA et al. Positive association between cerebral gray matter metabolism and dopamine D2/D3 receptor availability in healthy and schizophrenia subjects: An 18F-FDG and 18F-fallypride PET study. World J Biol Psychiatry. 2019 Oct; 7:1-15. PMID 31552783

Mitelman SA, Buchsbaum MS, Christian BT, Merrill BM, Adineh M, DeCastro A, Buchsbaum BR, Lehrer DS. Relationship between white matter glucose metabolism and fractional anisotropy in healthy and schizophrenia subjects. Psychiatry Research: Neuroimaging. 2020 May 30;299:111060. doi.org/10.1016/j.psychresns.2020/111060. PMID 32135405

Book Chapters (selected)

Hoffman RE, Lehrer DS, McGlashan TH. Alterations of Speech, Thought, Perception, and Self-experience. In: Tasman A, Kay J, Lieberman J, First MB, Riba MB (Eds.). Psychiatry, 4th edition.  John Wiley & Sons, Ltd., London, 2014.

Lehrer DS, Dougherty DD, Rauch SL. Brain Imaging in Psychiatry. In: Tasman A, Kay J, Lieberman J, First MB, Riba MB (Eds.). Psychiatry, 4th edition.  John Wiley & Sons, Ltd., London, 2014.

Is this you? Log in to update your profile.